PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 我们的目的是研究高龄对抗癫痫药物（AED）的药代动力学和代谢的影响。将对因任何原因服用苯妥英（PHT）或卡马西平（CBZ）作为单药治疗或与其他非干扰性药物（包括其他非干扰性AED）联合使用的选定老年和成年男性和女性门诊患者进行评价。患者将接受稳定标记制剂中CBZ或PHT口服剂量的一部分，100 mg静脉给药10分钟（仅一次）。稳定标记的CBZ和PHT不具有放射性，并且表现出与未标记的CBZ或PHT相同的动力学和代谢。将分析血液样本和尿液样本。 在CBZ去诱导研究（CBZ项目的子研究）中，受试者在三个月内的四个时间点接受静脉内制剂，同时停止CBZ方案并改用另一种抗癫痫药物（AED）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goal is to investigate the effect of advanced age on antiepileptic drug (AED) pharmacokinetics and metabolism. Selected elderly and adult male and female ambulatory patients taking phenytoin (PHT) or carbamazepine (CBZ) for any reason as monotherapy or with other non-interfering medications including other non-interfering AEDs will be evaluated. The patients will receive a portion of their oral dose of CBZ or PHT in a stable-labeled formulation given intravenously as 100 mg over 10 minutes (one time only). Stable-labeled CBZ and PHT are NOT radioactive and exhibit the same kinetics and metabolism as unlabeled CBZ or PHT. Blood samples and urine collections will be analyzed. In the CBZ De-Induction Study, a sub-study of the CBZ Project, subjects receive the intravenous formulation at four time points over three months while being taken off their CBZ regimen and switched to another antiepileptic drug (AED).